December 12, 2025

Dear Rett Community,

We are excited to share that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation, informed by the invaluable feedback we received from patients, caregivers and healthcare providers.

This new formulation is expected to deliver the same efficacy and safety profile of the original DAYBUE® (trofinetide) oral solution while offering children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their DAYBUE treatment.

DAYBUE STIX will be available on a limited basis starting in the first quarter of 2026 and more broadly early in the second quarter of 2026. The current oral solution formulation will also remain available.

At Acadia we are committed to providing the best possible experience for patients and their families who want to try DAYBUE STIX. Please speak with your healthcare provider or treating physician for more details.

More about DAYBUE STIX

DAYBUE STIX for oral solution is a new powder formulation that caregivers can mix with water-based liquids such as tea, lemonade, limeade or liquid hydration. The effectiveness and safety of DAYBUE STIX is based on the results of the LAVENDER™ study with DAYBUE oral solution in patients with Rett syndrome. The approval of this new formulation was informed by the results of a bioequivalence study, which demonstrated that both original DAYBUE oral solution and the new DAYBUE STIX for oral solution powder formulation provide comparable exposure. This confirmed bioequivalence means patients can expect the same efficacy and safety established by the oral solution formulation when using DAYBUE STIX.

We are so grateful to the Rett community for their support as we bring this new formulation to the families that need it.

All our best,
The Acadia Rett team